Patents

Issued U.S. Patents

• BIOMARKERS AND DIAGNOSTIC METHODS FOR ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS, US 9,958,460
• BIOMARKERS AND DIAGNOSTIC METHODS FOR ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS, US 11,619,637
• BIOMARKERS AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS, US 10,203,342
• QUANTIFICATION OF SUBPOPULATIONS OF EXOSOMES AND DIAGNOSIS OF NEUROGENERATIVE DISORDERS, US 11,852,635, B2

In addition to the issued U.S. patents, NanoSomiX has multiple patent application and continuations pending in the U.S. to cover its technology and clinical use in neurologic disorders.

Other Worldwide Patents

NanoSomiX also has additional issued patents in Israel, Japan, and Korea along with multiple pending worldwide applications covering the company’s technology and its use.